persistence versus reversion of 3tc resistance in hiv-1 determine the rate of emergence of nvp resistance持久性和降级3 tc抗hiv - 1确定一步耐药性的出现.pdfVIP

下载本文档

0
0
约10.87万字
约 23页
2017-09-11 发布于上海
举报
版权申诉

persistence versus reversion of 3tc resistance in hiv-1 determine the rate of emergence of nvp resistance持久性和降级3 tc抗hiv - 1确定一步耐药性的出现.pdf

1、本文档共23页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

persistence versus reversion of 3tc resistance in hiv-1 determine the rate of emergence of nvp resistance持久性和降级3 tc抗hiv - 1确定一步耐药性的出现

Viruses 2012, 4, 1212-1234; doi:10.3390/v4081212 OPEN ACCESS viruses ISSN 1999-4915 /journal/viruses Article Persistence versus Reversion of 3TC Resistance in HIV-1 Determine the Rate of Emergence of NVP Resistance Barbara A. Rath 1,2,*, Richard A. Olshen 3, Jerry Halpern 3 and Thomas C. Merigan 1 1 Center for AIDS Research, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; E-Mail: merigan@ 2 Department of Pediatrics, Division of Pneumonology-Immunology, Charité University Medical Center, Berlin 13353, Germany 3 Division of Biostatistics, Stanford University School of Medicine, Stanford, CA 94305, USA; E-Mails: olshen@ (R.A.O.); jerry.halpern@ (J.H.) * Author to whom correspondence should be addressed; E-Mail: Barbara.Rath@; Tel.: +49-30-450-666664; Fax: +49-30-690-88616. Received: 11 July 2012; in revised form: 3 August 2012 / Accepted: 6 August 2012 / Published: 7 August 2012 Abstract: When HIV-1 is exposed to lamivudine (3TC) at inhibitory concentrations, resistant variants carrying the reverse transcriptase (RT) substitution M184V emerge rapidly. This substitution confers high-level 3TC resistance and increased RT fidelity. We established a novel in vitro system to study the effect of starting nevirapine (NVP) in 3TC-resistant/NNRTI-naïve clinical isolates, and the impact of maintaining versus dropping 3TC pressure in this setting. Because M184V mutant HIV-1